Interleukin 10-Mediated Response and Correlated Anemia in a Patient with Advanced Non-Small Cell Lung Carcinoma

Anemia in cancer patients is associated with poor quality of life, reduced response to therapy, and decreased overall survival. We describe a case of a 56-year old woman with advanced metastatic non-small cell lung carcinoma who demonstrated marked response to a novel combinational immunotherapy app...

Descripción completa

Detalles Bibliográficos
Autores principales: Choucair, Khalil, Kelso, Jesse D., Duff, Joseph R., Cassidy, Christine S., Albrethsen, Mary T., Ashraf, Mushtaq, Verghese, Cherian, Oft, Martin, Brunicardi, F. Charles, Dworkin, Lance, Nemunaitis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489092/
https://www.ncbi.nlm.nih.gov/pubmed/31097939
http://dx.doi.org/10.1159/000499704
Descripción
Sumario:Anemia in cancer patients is associated with poor quality of life, reduced response to therapy, and decreased overall survival. We describe a case of a 56-year old woman with advanced metastatic non-small cell lung carcinoma who demonstrated marked response to a novel combinational immunotherapy approach involving a long-acting PEGylated construct of recombinant human Interleukin-10 with Nivolumab, an anti-PD-L1 checkpoint inhibitor. While on treatment, the patient developed severe anemia and hyper-ferritinemia requiring RBC transfusion support. Here we discuss a possible novel immune mechanism of IL10-mediated anemia in correlation with tumor response.

Ejemplares similares